The c-Myc oncoprotein and Akt are capable of conferring a selective advantage to cancer cells by stimulating proliferation, cell survival, metastasis and drug resistance.26,27 Thus, CIP2A promotes MM cell proliferation, at least in part, through Akt and c-Myc activation. Here, CIP2A is linked to Miyoshi myopathy.